- Home
- TSHA vs NRC Comparison
TSHA vs NRC Comparison
Compare TSHA & NRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- NRC
- Stock Information
- Founded
- TSHA 2019
- NRC 1981
- Country
- TSHA United States
- NRC United States
- Employees
- TSHA N/A
- NRC N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- NRC Biotechnology: Commercial Physical & Biological Resarch
- Sector
- TSHA Health Care
- NRC Health Care
- Exchange
- TSHA Nasdaq
- NRC Nasdaq
- Market Cap
- TSHA 403.7M
- NRC 426.3M
- IPO Year
- TSHA 2020
- NRC N/A
- Fundamental
- Price
- TSHA $2.06
- NRC $19.14
- Analyst Decision
- TSHA Strong Buy
- NRC
- Analyst Count
- TSHA 8
- NRC 0
- Target Price
- TSHA $6.63
- NRC N/A
- AVG Volume (30 Days)
- TSHA 6.0M
- NRC 81.0K
- Earning Date
- TSHA 11-13-2024
- NRC 10-25-2024
- Dividend Yield
- TSHA N/A
- NRC 2.51%
- EPS Growth
- TSHA N/A
- NRC N/A
- EPS
- TSHA N/A
- NRC 1.12
- Revenue
- TSHA $9,915,000.00
- NRC $144,155,000.00
- Revenue This Year
- TSHA N/A
- NRC N/A
- Revenue Next Year
- TSHA N/A
- NRC N/A
- P/E Ratio
- TSHA N/A
- NRC $17.05
- Revenue Growth
- TSHA N/A
- NRC N/A
- 52 Week Low
- TSHA $1.19
- NRC $17.62
- 52 Week High
- TSHA $4.32
- NRC $42.38
- Technical
- Relative Strength Index (RSI)
- TSHA 55.32
- NRC 46.67
- Support Level
- TSHA $1.19
- NRC $18.93
- Resistance Level
- TSHA $2.63
- NRC $21.64
- Average True Range (ATR)
- TSHA 0.24
- NRC 0.84
- MACD
- TSHA 0.08
- NRC 0.14
- Stochastic Oscillator
- TSHA 60.42
- NRC 37.81
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.